Loading clinical trials...

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients | Clinical Trials | Clareo Health

TERMINATEDPHASE1/PHASE2

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Phase I/II Study of the Safety of Subcutaneous Interferon Gamma-1b Combined With Rituximab in Patients With Low Grade/Follicular Non-Hodgkin's Lymphoma

NCT00057447•InterMune

View on ClinicalTrials.gov

Summary

Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Relapsed or progressive low-grade/follicular NHL who are candidates for rituximab therapy
•Patients who were on other therapy including CHOP or radiation
•Previous therapy must have concluded 30 days prior to enrollment
•Demonstrable CD20-positive tumor population in lymph nodes or bone marrow

Locations (1)

Intermune Inc

Brisbane, California, United States

Key Dates

Start Date

March 1, 2003

Completion Date

June 1, 2004

Last Updated

November 1, 2007

Enrollment

ACTUAL participants

Conditions

Non-Hodgkin's Lymphoma

Interventions

Interferon Gamma-1b

DRUG

Rituximab

DRUG

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

NCT06667687

Non-Hodgkin's Lymphoma

View study

RECRUITINGPHASE1/PHASE2

A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT05623982

Non-hodgkin's Lymphoma

View study

RECRUITINGPHASE2

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 1, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Inclusion Criteria

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation